Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALTEANA is an anti-tetanus vaccine developed by the Slovak pharmaceutical company Imuna Pharm. It is composed of tetanus toxin that has been inactivated by formaldehyde (tetanus toxoid or anatoxin) and purified to maintain its antigenicity. To enhance the immune response, the toxoid is adsorbed onto a mineral carrier, specifically aluminum hydroxide. The vaccine is indicated for the active immunization of children and adults against tetanus, as well as for post-traumatic prophylaxis in individuals with incomplete or undocumented vaccination history. Upon intramuscular administration, ALTEANA stimulates the production of specific antibodies against the tetanus toxin, providing protection against infection by *Clostridium tetani*.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ALTEANA.